Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works

Coronaviruses: An Overview of Their Replication and Pathogenesis

Fehr, A. R., & Perlman, S. M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,807 · see citing works

Structural basis of receptor recognition by SARS-CoV-2

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852 · see citing works

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Coutard, B., Valle, C., de Lamballerie, X. N., Canard, B., Seidah, N. G., & Decroly, É. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104742 · Cited by 1,685 · see citing works

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434 · see citing works

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sia, S. F., Yan, L.-M., Chin, A. W. H., Fung, K., Choy, K.-T., Wong, A. Y. L., Kaewpreedee, P., Perera, R. A. P. M., Poon, L. L. M., Nicholls, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2342-5 · Cited by 1,303 · see citing works

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303 · see citing works

Distinct conformational states of SARS-CoV-2 spike protein

Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221 · see citing works

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Ke, Z., Otón, J., Qu, K., Cortese, M., Žíla, V., McKeane, L., Nakane, T., Zivanov, J., Neufeldt, C. J., Cerikan, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2665-2 · Cited by 1,114 · see citing works

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · see citing works

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · see citing works

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Chan, J., Zhang, A., Yuan, S.-F., Poon, V., Chan, C., Lee, A., Chan, W., Fan, Z., Tsoi, H.-W., Wen, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa325 · Cited by 1,034 · see citing works

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Imai, M., Iwatsuki‐Horimoto, K., Hatta, M., Loeber, S. J., Halfmann, P., Nakajima, N., Watanabe, T., Ujie, M., Takahashi, K., Ito, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009799117 · Cited by 977 · see citing works

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816 · see citing works

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works

Rapid COVID-19 vaccine development

Graham, B. S. (2020) · Science · doi:10.1126/science.abb8923 · Cited by 771 · see citing works

Pre-fusion structure of a human coronavirus spike protein

Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2016) · Nature · doi:10.1038/nature17200 · Cited by 765 · see citing works

Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins

Xiao, K., Zhai, J., Feng, Y., Zhou, N., Zhang, X., Zou, J.-J., Li, N., Guo, Y., Li, X., Shen, X., et al. (2020) · Nature · doi:10.1038/s41586-020-2313-x · Cited by 728 · see citing works

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 727 · see citing works

The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control

Helmy, Y. A., Fawzy, M., Elaswad, A., Sobieh, A., Kenney, S. P., & Shehata, A. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041225 · Cited by 687 · see citing works

mRNA vaccine delivery using lipid nanoparticles

Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624 · see citing works

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., Roose, K., van Schie, L., Hoffmann, M., Pöhlmann, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.031 · Cited by 610 · see citing works

SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview

Rabaan, A. A., Al-Ahmed, S. H., Haque, S., Sah, R., Tiwari, R., Malik, Y. S., Dhama, K., Yatoo, M. I., Bonilla‐Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · PubMed · Cited by 592 · see citing works

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 555 · see citing works

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Wrobel, A. G., Benton, D. J., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0468-7 · Cited by 544 · see citing works

Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer

Walls, A. C., Tortorici, M. A., Bosch, B., Frenz, B., Rottier, P. J. M., DiMaio, F., Rey, F. A., & Veesler, D. (2016) · Nature · doi:10.1038/nature16988 · Cited by 539 · see citing works

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · see citing works

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., Zhou, J., Bouton, C. R., Rogers, P., Polra, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17409-9 · Cited by 462 · see citing works

Molecular cloning : a laboratory manual. Cold Spring Harbor, NY

Sambrook, H. C. (1989) · Medical Entomology and Zoology · Cited by 368 · see citing works

Furin‐mediated protein processing in infectious diseases and cancer

Braun, E., & Sauter, D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1073 · Cited by 345 · see citing works

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Huo, J., Zhao, Y., Ren, J., Zhou, D., Duyvesteyn, H. M. E., Ginn, H. M., Carrique, L., Malinauskas, T., Ruza, R. R., Shah, P. N. M., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.010 · Cited by 317 · see citing works

Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding

Klumperman, J., Locker, J. K., Meijer, A., Horzinek, M. C., Geuze, H. J., & Rottier, P. J. M. (1994) · Journal of Virology · doi:10.1128/jvi.68.10.6523-6534.1994 · Cited by 314 · see citing works

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Tostanoski, L. H., Wegmann, F., Martinot, A. J., Loos, C., McMahan, K., Mercado, N. B., Yu, J., Chan, C. N., Bondoc, S., Starke, C. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1070-6 · Cited by 269 · see citing works

Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters

Osterrieder, N., Bertzbach, L. D., Dietert, K., Abdelgawad, A., Vladimirova, D., Kunec, D., Hoffmann, D., Beer, M., Gruber, A. D., & Trimpert, J. (2020) · Viruses · doi:10.3390/v12070779 · Cited by 218 · see citing works

A model of the ACE2 structure and function as a SARS-CoV receptor

Prabakaran, P., Xiao, X., & Dimitrov, D. S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.081 · Cited by 209 · see citing works

The Cytoplasmic Tail of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains a Novel Endoplasmic Reticulum Retrieval Signal That Binds COPI and Promotes Interaction with Membrane Protein

McBride, C. E., Li, J., & Machamer, C. (2006) · Journal of Virology · doi:10.1128/jvi.02146-06 · Cited by 188 · see citing works

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Sánchez-Felipe, L., Vercruysse, T., Sharma, S., Ma, J., Lemmens, V., Looveren, D. V., Javarappa, M. P. A., Boudewijns, R., Malengier‐Devlies, B., Liesenborghs, L., et al. (2020) · Nature · doi:10.1038/s41586-020-3035-9 · Cited by 174 · see citing works

Intracellular Targeting Signals Contribute to Localization of Coronavirus Spike Proteins near the Virus Assembly Site

Lontok, E., Corse, E., & Machamer, C. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5913-5922.2004 · Cited by 157 · see citing works

Understanding the T cell immune response in SARS coronavirus infection

Oh, H. J., Gan, S. K., Bertoletti, A., & Tan, Y. (2012) · Emerging Microbes & Infections · doi:10.1038/emi.2012.26 · Cited by 152 · see citing works

Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2

Wang, S., Guo, F., Liu, K., Wang, H., Rao, S., Yang, P., & Jiang, C. (2008) · Virus Research · doi:10.1016/j.virusres.2008.03.004 · Cited by 134 · see citing works

An overview of coronaviruses including the SARS-2 coronavirus – Molecular biology, epidemiology and clinical implications

Kaul, D. (2020) · Current Medicine Research and Practice · doi:10.1016/j.cmrp.2020.04.001 · Cited by 113 · see citing works

Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy

DeRosa, F., Smith, L., Shen, Y., Huang, Y., Pan, J., Xie, H., Yahalom, B., & Heartlein, M. W. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.001 · Cited by 111 · see citing works

Prediction of the Folding Pathways and Structure of the GCN4 Leucine Zipper

Vieth, M., Koliński, A., Brooks, C. L., & Skolnick, J. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1239 · Cited by 108 · see citing works

The SARS-CoV-2 Coronavirus and the COVID-19 Outbreak

Lauxmann, M. A., Santucci, N. E., & Autrán-Gómez, A. M. (2020) · International braz j urol · doi:10.1590/s1677-5538.ibju.2020.s101 · Cited by 106 · see citing works

The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cellsPreprint

Peacock, T. P., Goldhill, D. H., Zhou, J., Baillon, L., Frise, R., Swann, O. C., Kugathasan, R., Penn, R., Brown, J. C., Sanchez-David, R. Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.30.318311 · Cited by 88 · see citing works

Direct visualization of translational GTPase factor pool formed around the archaeal ribosomal P-stalk by high-speed AFM

Imai, H., Uchiumi, T., & Kodera, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018975117 · Cited by 88 · see citing works

COVID-19: Time to exonerate the pangolin from the transmission of SARS-CoV-2 to humans

Frutos, R., Cobo, J. S., Chen, T., & Devaux, C. A. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104493 · Cited by 87 · see citing works

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Huo, J., Zhao, Y., Ren, J., Zhou, D., Duyvesteyn, H. M. E., Ginn, H. M., Carrique, L., Malinauskas, T., Ruza, R. R., Shah, P. N. M., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.002 · Cited by 79 · see citing works

A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike GlycoproteinPreprint

Joyce, M. G., Sankhala, R. S., Chen, W., Choe, M., Bai, H., Hajduczki, A., Yan, L., Sterling, S. L., Peterson, C. E., Green, E. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.15.992883 · Cited by 47 · see citing works

Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development

Begum, J., Mir, N. A., Dev, K., Buyamayum, B., Wani, M. Y., & Raza, M. (2020) · Transboundary and Emerging Diseases · doi:10.1111/tbed.13804 · Cited by 45 · see citing works

Natural Polymorphisms Are Present in the Furin Cleavage Site of the SARS-CoV-2 Spike Glycoprotein

Xing, Y., Li, X., Gao, X., & Dong, Q. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00783 · Cited by 41 · see citing works

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

Kroemer, M., Spehner, L., Vettoretti, L., Bouard, A., Eberst, G., Pili‐Floury, S., Capellier, G., Lepiller, Q., Orillard, É., Mansi, L., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.08.036 · Cited by 35 · see citing works

A Novel Glycoprotein of Feline Infectious Peritonitis Coronavirus Contains a KDEL-like Endoplasmic Reticulum Retention Signal

Vennema, H., Heijnen, L., Rottier, P. J. M., Horzinek, M. C., & Spaan, W. J. M. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2996-5_33 · Cited by 31 · see citing works

A novel glycoprotein of feline infectious peritonitis coronavirus contains a KDEL-like endoplasmic reticulum retention signal

Vennema, H., Heijnen, L., Rottier, P. J. M., Horzinek, M. C., & Spaan, W. J. M. (1992) · Journal of Virology · doi:10.1128/jvi.66.8.4951-4956.1992 · Cited by 28 · see citing works

A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes

Stefano, M. L., Kream, R. M., & Stefano, G. B. (2020) · Medical Science Monitor · doi:10.12659/msm.926016 · Cited by 26 · see citing works

Author Correction: SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Wrobel, A. G., Benton, D. J., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0509-2 · Cited by 22 · see citing works

[Progress and challenge of vaccine development against 2019-novel coronavirus (2019-nCoV)].

Shi, Y., Wang, N., & Zou, Q. (2020) · PubMed · doi:10.3760/cma.j.cn112150-20200317-00366 · Cited by 21 · see citing works

HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity

Yin, R., Zheng, W., Hao, F., Yang, X.-C., Zhong, B.-Y., & Li, Q.-J. (2009) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.04.008 · Cited by 12 · see citing works

The clinical progress of mRNA vaccines and immunotherapies

Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823 · see citing works

mRNA-based therapeutics: powerful and versatile tools to combat diseases

Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 801 · see citing works

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine

Li, C., Lee, A., Grigoryan, L., Arunachalam, P. S., Scott, M. K. D., Trisal, M., Wimmers, F., Sanyal, M., Weidenbacher, P. A., Feng, Y., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01163-9 · Cited by 505 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

mRNA Vaccines in the COVID-19 Pandemic and Beyond

Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 252 · see citing works

Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines

Chatzikleanthous, D., O’Hagan, D. T., & Adamo, R. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00447 · Cited by 150 · see citing works

Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity

Tsai, S. J., Atai, N. A., Cacciottolo, M., Nice, J., Salehi, A., Guo, C., Sedgwick, A., Kanagavelu, S., & Gould, S. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101266 · Cited by 142 · see citing works

Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza

Chivukula, S., Plitnik, T., Tibbitts, T., Karve, S., Dias, A., Zhang, D., Goldman, R., Gopani, H., Khanmohammed, A., Sarode, A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00420-6 · Cited by 117 · see citing works

Frameworks for transformational breakthroughs in RNA-based medicines

Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 93 · see citing works

Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination

Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 88 · see citing works

Advanced technologies for the development of infectious disease vaccines

Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 85 · see citing works

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies

Kozlovskaya, L., Piniaeva, A., Ignatyev, G., Gordeychuk, I., Volok, V., Rogova, Y. V., Shishova, A., Kovpak, A., Ivin, Y., Antonova, L., et al. (2021) · Emerging Microbes and Infections · doi:10.1080/22221751.2021.1971569 · Cited by 73 · see citing works

A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera

Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105370 · Cited by 70 · see citing works

Delivery of mRNA for regulating functions of immune cells

Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62 · see citing works

Development and applications of mRNA treatment based on lipid nanoparticles

Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57 · see citing works

SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern

Lu, M., Chamblee, M., Zhang, Y., Ye, C., Dravid, P., Park, J., Mahesh, K., Trivedi, S., Murthy, S. S., Sharma, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110105119 · Cited by 54 · see citing works

An Update on mRNA-Based Viral Vaccines

Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49 · see citing works

mRNA vaccines in the prevention and treatment of diseases

Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 51 · see citing works

Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates

Pavot, V., Berry, C., Kishko, M., Anosova, N. G., Huang, D., Tibbitts, T., Raillard, A., Gautheron, S., Gutzeit, C., Koutsoukos, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29219-2 · Cited by 40 · see citing works

Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model

Chen, Y., Li, C., Liu, F., Ye, Z., Song, W., Lee, A. C.-Y., Shuai, H., Lu, L., To, K. K., Chan, J. F., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2026741 · Cited by 43 · see citing works

Revolutionizing Nanovaccines: A New Era of Immunization

Saleh, M. A., El-Moghazy, A. Y., El-Gohary, A. H., Saber, W. I. A., & Helmy, Y. A. (2025) · Vaccines · doi:10.3390/vaccines13020126 · Cited by 46 · see citing works

Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters

Li, L., Honda-Okubo, Y., Baldwin, J., Bowen, R., Bielefeldt-Ohmann, H., & Petrovsky, N. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.041 · Cited by 38 · see citing works

Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies

Du, L., Yang, Y., Zhang, X., & Li, F. (2021) · Nanoscale · doi:10.1039/d1nr03831a · Cited by 41 · see citing works

From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics

Korzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., Taratula, O., & Marks, D. L. (2023) · Pharmaceuticals · doi:10.3390/ph16081088 · Cited by 37 · see citing works

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern

Hawman, D. W., Meade-White, K., Archer, J. F., Leventhal, S. S., Wilson, D., Shaia, C., Randall, S., Khandhar, A. P., Krieger, K., Hsiang, T.-Y., et al. (2022) · eLife · doi:10.7554/elife.75537 · Cited by 34 · see citing works

Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque

Sohi, A. N., Kiani, J., Arefian, E., Khosrojerdi, A., Fekrirad, Z., Ghaemi, S., Zim, M. K., Jalili, A., Bostanshirin, N., & Soleimani, M. (2021) · Vaccines · doi:10.3390/vaccines9091007 · Cited by 32 · see citing works

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

Tabynov, K., Turebekov, N. A., Babayeva, M., Fomin, G., Yerubayev, T., Yespolov, T. I., Li, L., Renukaradhya, G. J., Petrovsky, N., & Tabynov, K. K. (2022) · npj Vaccines · doi:10.1038/s41541-022-00450-8 · Cited by 33 · see citing works

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 32 · see citing works

COVID-19 Vaccine Platforms: Challenges and Safety Contemplations

Al-Jighefee, H. T., Najjar, H., Ahmed, M. N., Qush, A., Awwad, S., & Kamareddine, L. (2021) · Vaccines · doi:10.3390/vaccines9101196 · Cited by 27 · see citing works

SARS-CoV-2 and the host-immune response

Maison, D. P., Deng, Y., & Gerschenson, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195871 · Cited by 29 · see citing works

A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models

Warner, N. L., Archer, J. F., Park, S., Singh, G., McFadden, K. M., Kimura, T., Nicholes, K., Simpson, A., Kaelber, J. T., Hawman, D. W., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi1625 · Cited by 25 · see citing works

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

Kandimalla, R. J. L., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P. H., Feo, V. D., & Dewanjee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9111740 · Cited by 25 · see citing works

Vaccines against SARS-CoV-2 variants and future pandemics

Park, T., Hwang, H., Moon, S., Kang, S. G., Song, S., Kim, Y. H., Kim, H., Ko, E., Yoon, S., Kang, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110075 · Cited by 23 · see citing works

Advancing mRNA vaccines: A comprehensive review of design, delivery, and efficacy in infectious diseases

Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 26 · see citing works

Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery

Broudic, K., Amberg, A., Schaefer, M. K., Spirkl, H.-P., Bernard, M., & Désert, P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116143 · Cited by 25 · see citing works

An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters

Tabynov, K., Solomadin, M., Turebekov, N. A., Babayeva, M., Fomin, G., Yadagiri, G., Renu, S., Yerubayev, T., Petrovsky, N., Renukaradhya, G. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39402-0 · Cited by 23 · see citing works

An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations

Kantarcıoğlu, B., Iqbal, O., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Ligocki, M. A., Jeske, W. P., Adıgüzel, C., Gerotziafas, G., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211056648 · Cited by 24 · see citing works

Computational design of vaccine immunogens

Castro, K. M., Scheck, A., Xiao, S., & Correia, B. E. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102821 · Cited by 22 · see citing works

COVID-19 clinical presentation, management, and epidemiology: a concise compendium

Maison, D. P., Tasissa, H., Deitchman, A. N., Peluso, M. J., Deng, Y., Miller, F. D., Henrich, T. J., & Gerschenson, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1498445 · Cited by 22 · see citing works

The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA

Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 21 · see citing works

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · doi:10.1101/2021.05.13.443734 · Cited by 18 · see citing works

Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates

Pavot, V., Berry, C., Kishko, M., Anosova, N. G., Li, L., Tibbitts, T., Huang, D., Raillard, A., Gautheron, S., Gutzeit, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36908-z · Cited by 18 · see citing works

Nonclinical safety assessment of an mRNA Covid‐19 vaccine candidate following repeated administrations and biodistribution

Broudic, K., Laurent, S., Perkov, V., Simon, C., Garinot, M., Truchot, N., Latour, J., & Désert, P. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4548 · Cited by 14 · see citing works

Endosomal escape and current obstacles in ionizable lipid nanoparticles mediated gene delivery: lessons from COVID-19 vaccines

Meerasa, S. S., Ahmad, A., Khan, A. A., Haque, S., & Saleem, I. Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126263 · Cited by 14 · see citing works

A Lyme disease mRNA vaccine targeting Borrelia burgdorferi OspA induces strong immune responses and prevents transmission in mice

Tahir, D., Geolier, V., Bruant, H., Flèche‐Matéos, A. L., Mallet, A., Varloud, M., Civat, C., Girerd-Chambaz, Y., Montano, S., Pion, C., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102514 · Cited by 15 · see citing works

An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge

Honda-Okubo, Y., Li, L., Andre, G., Leong, K. H., Howerth, E., Bebin-Blackwell, A.-G., Ross, T., & Petrovsky, N. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.063 · Cited by 12 · see citing works

Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity

Muñoz-Alía, M. Á., Nace, R. A., Balakrishnan, B., Zhang, L., Packiriswamy, N., Singh, G., Warang, P., Mena, I., Narjari, R., Vandergaast, R., et al. (2024) · mBio · doi:10.1128/mbio.02928-23 · Cited by 11 · see citing works

Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations

Helmy, S. A., Morsi, R. M. E., El-Masry, S. M., & El-Masry, S. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103762 · Cited by 12 · see citing works

mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious Diseases

Sokhangouy, S. K., Behzadi, M., Rezaei, S., Farjami, M., Haghshenas, M., Sefidbakht, Y., & Mozaffari‐Jovin, S. (2025) · Biotechnology Journal · doi:10.1002/biot.202400596 · Cited by 9 · see citing works

Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model

Kalnin, K. V., Plitnik, T., Kishko, M., Huang, D., Raillard, A., Piolat, J., Anosova, N. G., Tibbitts, T. J., DiNapoli, J. M., Karve, S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.021 · Cited by 10 · see citing works

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

Chen, J., Wang, X., Li, L., Yi, L., Jiang, Y., Hao, P., Xu, Z., Zou, W., Li, P., Gao, Z., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.967493 · Cited by 9 · see citing works

In vitro high-content tissue models to address precision medicine challenges

Afewerki, S., Stocco, T. D., Silva, A. D. R., Furtado, A. S. A., de Sousa, G. F., Ruiz‐Esparza, G. U., Webster, T. J., Marciano, F. R., Strømme, M., Zhang, Y. S., et al. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101108 · Cited by 8 · see citing works

Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction

Saha, A., Choudhary, S., Walia, P., Kumar, P., & Tomar, S. (2025) · Virology · doi:10.1016/j.virol.2025.110394 · Cited by 8 · see citing works

Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques

Willcox, A. C., Sung, K., Garrett, M. E., Galloway, J., O’Connor, M. A., Erasmus, J. H., Logue, J. K., Hawman, D. W., Chu, H. Y., Hasenkrug, K. J., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010155 · Cited by 9 · see citing works

SARS-CoV-2 S Glycoprotein Stabilization Strategies

Pedenko, B., Sulbarán, G., Guilligay, D., Effantin, G., & Weissenhorn, W. (2023) · Viruses · doi:10.3390/v15020558 · Cited by 7 · see citing works

A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants

Ao, D., Peng, D., He, C., Ye, C., Hong, W., Huang, X., Lu, Y., Shi, J., Zhang, Y., Liu, J., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00258-7 · Cited by 6 · see citing works

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development

Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 7 · see citing works

Lipid Nanoparticle-Mediated Delivery of Therapeutic and Prophylactic mRNA: Immune Activation by Ionizable Cationic Lipids

Ongun, M., Lokras, A. G., Foged, C., & Thakur, A. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_11 · Cited by 4 · see citing works

Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters

Berry, C., Pavot, V., Anosova, N. G., Kishko, M., Li, L., Tibbitts, T., Raillard, A., Gautheron, S., Cummings, S., Bangari, D. S., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00302-z · Cited by 4 · see citing works

A Critical Assessment of COVID-19 Genomic Vaccines

Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 3 · see citing works

Nanotechnology laying new foundations for combating COVID-19 pandemic

Jain, S., Hussain, A., Bhatt, A., Nasa, A., Navani, N. K., & Mutreja, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90538-1.00019-4 · Cited by 3 · see citing works

SARS-CoV-2: An Analysis of the Vaccine Candidates Tested in Combatting and Eliminating the COVID-19 Virus

Elmancy, L., Alkhatib, H., & Daou, A. (2022) · Vaccines · doi:10.3390/vaccines10122086 · Cited by 3 · see citing works

Optimizing mouse models for mRNA vaccines: addressing dose translation challenges

Chang, Z. W., Tan, Y. J., Liao, Y., Goh, Y. S., Kabir, S. R., Wang, Y., Hor, P. X., Loh, C. Y., Huang, Y., Wang, B., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-47820-z · Cited by 2 · see citing works

The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection

Xue, V. W., Wong, S. C. C., Li, B., & Cho, W. C. S. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2218083 · Cited by 2 · see citing works

Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme

Bernadin, O., Cochin, M., Driouich, J., Laprie, C., Steigler, P., Boukes, G. J., Fenner, C., de Lamballerie, X. N., & Nougaırède, A. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126378 · Cited by 1 · see citing works

Emerging Biopharmaceutical Technologies and Trends

Wood, D. W., & Gierach, I. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_19 · Cited by 1 · see citing works

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

Ávila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46714-w · Cited by 1 · see citing works

Expression system and purification process for the vaccine production

Vuppu, S., Mishra, T., Gholap, A. D., Balar, P. C., Gogoi, N. R., & Chavda, V. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00021-7 · Cited by 1 · see citing works

Macaque-human differences in SARS-CoV-2 Spike antibody response elicited by vaccination or infectionPreprint

Willcox, A. C., Sung, K., Garrett, M. E., Galloway, J., O’Connor, M. A., Erasmus, J. H., Logue, J. K., Hawman, D. W., Chu, H. Y., Hasenkrug, K. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.01.470697 · Cited by 1 · see citing works

Broad neutralization of SARS-CoV-2 variants by circular mRNA producing VFLIP-X spike in micePreprint

Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.17.484759 · Cited by 1 · see citing works

SARS-CoV-2 Spike receptor-binding domain entrapped in mannose-conjugated chitosan nanoparticle vaccine delivered intranasal elicits local and systemic Th1 and Th2 immune responses in mice and antiviral efficacy in Syrian hamstersPreprint

Tabynov, K., Solomadin, M., Turebekov, N. A., Babayeva, M., Fomin, G., Yadagiri, G., Renu, S., Yerubayev, T., Yespolov, T. I., Petrovsky, N., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2192392/v1 · Cited by 1 · see citing works

Design and Development of mRNA Vaccines to Combat the COVID ‐19 Pandemic

Tombácz, I. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch8 · Cited by 1 · see citing works

Human vaccines & immunotherapeutics: news

(2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1921459

SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesPreprint

Pavot, V., Berry, C., Kishko, M., Anosova, N. G., Huang, D., Tibbitts, T., Raillard, A., Gautheron, S., Gutzeit, C., Koutsoukos, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.20.461023

Beta variant COVID-19 protein booster vaccines elicit durable cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesPreprint

Pavot, V., Berry, C., Kishko, M., Anosova, N. G., Li, L., Tibbitts, T., Raillard, A., Gautheron, S., Gutzeit, C., Koutsoukos, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2372287/v1

Animal Pre-Clinical Study of an Inactivated SARS-CoV-2 Vaccine candidate (Osvid-19 ®): Immunogenicity, Protective, and Safety Aspects

(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.09.013

Enhanced Omicron subvariant cross-neutralization efficacy of a monovalent SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigenPreprint

Seo, H. Y., Jung, H., Woo, H., Jung, H.-G., Cho, H., Bak, Y., Lee, S., Son, Y.-M., Yoon, G., Hwang, S.-Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.10.557088

Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigenPreprint

Oh, J., Seo, H. Y., Jung, H., Woo, H., Jung, H.-G., Cho, H., Bak, Y., Lee, S., Son, Y.-M., Yoon, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3344007/v1

Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines

de Bruyn, G., Adhikarla, H., Brackett, C., Jia, Y., Premkumar, L., Mudrak, S. V., Sawant, S. S., Zhang, D., Chicz, R. M., Sridhar, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01203-z

Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines

Liu, R., Patterson, L. D., Yeasmin, M., Kim, K., Park, B. R., Bhatnagar, N., Raha, J. R., Grovenstein, P. B., Pal, S. S., Le, C. T. T., et al. (2026) · Virology · doi:10.1016/j.virol.2026.110884

Evaluation of the minipig as an alternative model based on cross-study comparisons with rabbit in mRNA vaccine safety assessment

Broudic, K., Correia, M., Laurent, S., Elies, L., Fant, P., Vaure, C., Truchot, N., & Désert, P. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118093

Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates

Kalnin, K. V., Plitnik, T., Kishko, M., Zhang, J., Zhang, D., Beauvais, A., Anosova, N. G., Tibbitts, T., DiNapoli, J. M., Huang, P.-W. D., et al. (2020) · doi:10.1101/2020.10.14.337535 · Cited by 18 · see citing works

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines · doi:10.1038/s41541-021-00311-w · Cited by 165 · see citing works

Ferritin-binding and ubiquitination-modified mRNA vaccines induce potent immune responses and protective efficacy against SARS-CoV-2

Yu, T., Zhang, C., Xing, J.-H., Zhang, T., Xu, Z., Di, Y., Yang, S., Jiang, R., Tang, J., Zhuang, X., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111630 · Cited by 10 · see citing works

Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models

Lelis, F., Byk, L. A., Pustylnikov, S., Nguyen, V., Nguyen, B. T., Nitz, M., Tarte, P., Tungare, K., Li, J., Manna, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46233-6 · Cited by 10 · see citing works

Preclinical data from SARS-CoV-2 mRNA vaccine

Vabret, N. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0377-3 · Cited by 13 · see citing works